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Abstract
Background
There are few data relating to sirolimus overdose in the medical literature. Our objectives
were to describe all cases of overdose with sirolimus reported to Swiss, German and Aus-
trian Poisons Centres between 2002-2013.
Methods
An observational case-series analysis was performed to determine circumstances, magni-
tude, management and outcome of sirolimus overdose.
Results
Five cases of acute sirolimus overdose were reported – three in young children and two in
adults. Four were accidental and one was with suicidal intent. Two patients developed
symptoms probably related to sirolimus overdose: mild elevation of alkaline phosphatase,
fever and gastroenteritis in a 2.5-year-old male who ingested 3 mg, and mild changes in
total cholesterol in an 18-year-old female after ingestion of 103 mg. None of these events
were life-threatening. Serial blood concentration measurements were performed starting 24
h after ingestion of 103 mg in a single case, and these followed a similar pharmacokinetic
time-course to measurements taken after dosing in the therapeutic range.
Conclusions
Acute sirolimus overdose occurred accidentally in the majority of cases. Even large over-
doses appeared to be well-tolerated, however children might be at greater risk of developing
complications. Further study of sirolimus overdose is needed.
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Introduction
Sirolimus (formerly rapamycin) is an immunosuppressive agent licensed for the prophylaxis of
organ rejection in renal transplant recipients [1]. It is recommended that sirolimus be used ini-
tially in combination with cyclosporine and corticosteroids, with subsequent withdrawal of cy-
closporine as necessary [1]. It is also used off-label in other types of organ transplant. Sirolimus
inhibits activation and proliferation of T lymphocytes and antibody production by a distinct
mechanism. In cells, it binds to the immunophilin, FK Binding Protein-12 (FKBP-12). The re-
sulting complex in turn inhibits the activation of a key regulatory kinase, mammalian target of
rapamycin (mTOR). Failure to activate mTOR results in inhibition of Interleukin-2-driven T-
cell proliferation [2].
Sirolimus is a cytochrome P450 3A4 and P-glycoprotein substrate, making it susceptible to
interactions with drugs that induce or inhibit the activity of these drug-handling proteins [1].
The maximum licensed starting dose of oral sirolimus in combination with cyclosporine (a cy-
tochrome P450 3A4 and P-glycoprotein inhibitor) for adults and children over 13 years in
Switzerland is 6 mg/day [1]. Absorption and metabolism of sirolimus is highly variable [3], and
this results in great differences in blood concentrations between patients who have received the
same dose. Subsequent dosing is therefore guided according to trough whole blood concentra-
tions. A target trough concentration range of 5–15 μg/L when sirolimus is used concomitantly
with cyclosporine and prednisone has been shown to be associated with effective rejection pro-
phylaxis with minimal concentration-dependent adverse effects (leucopenia, thrombocytope-
nia, and hypertriglyceridemia) [3]. In the absence of cyclosporine, a four-fold increase in dose
is usually required, however it is recommended that the daily dose should not exceed 40 mg
[1]. Hypercholesterolaemia is a commonly reported adverse effect of sirolimus [1], however it
appears to be only weakly dose-related [3].
Patients taking sirolimus or their household contacts who could have access to their drugs
may be exposed to overdose, however, little is known about the effects of sirolimus in acute over-
dose. Sirolimus has a long half-life (62 ± 12 h in a study of renal transplant patients receiving
concomitant cyclosporine and prednisone [4]), therfore a single overdose may have a prolonged
effect. One source briefly mentions two cases of overdose with sirolimus [5]. In the first case, in-
gestion of 120 mg sirolimus was well tolerated, and in the second case atrial fibrillation developed
after ingestion of 150 mg. A dose-escalation study in renal transplant patients taking cyclospor-
ine examined the effect of single doses up to 15 mg/m2 [5, 6]. The only safety issues which arose
were a case of transient thrombocytopenia (probably related to the single 28 mg sirolimus dose)
and a case of mild epistaxis (possibly related to the single 21 mg sirolimus dose). A further study
administered single doses of 21 mg/m2 to three stable renal transplant patients receiving cyclo-
sporine [7], none of whom experienced toxicity. All this information relates to adults. There are
no reports in the literature of sirolimus overdose during the post-marketing period.
The purpose of this study was to investigate the circumstances, management and outcomes
of overdoses with sirolimus in adults and children using data reported to Swiss, German, and
Austrian poisons centres.
Materials and Methods
Study design and inclusion criteria
A specific ethics approval was not required for this observational study due to the nature of the
study design according to the regulations of the cantonal ethics committee Zurich, Switzerland
at the time when the study was performed which also stated that anonymised data generated
during patient care can be used retrospectively for research purposes without obtaining written
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consent. The clinical toxicologist who first advised on a case assigned it an internal unique case
identifier. Once all data pertaining to the case (including follow up) had been obtained, the
case was closed and the data—excluding patient-identifying information—was exported to a
research database. This research database to which the authors had access therefore did not
contain any patient-identifying information.
We performed a multicentre retrospective review of all acute overdoses involving sirolimus
in adults and children (<16 years) either alone or in combination with other drugs that have
been reported anonymously according to the Codex of the Society of Clinical Toxicology
(GfKT) [8] to Swiss (Zurich), German (Berlin, Bonn, Erfurt, Freiburg, Göttingen, Mainz, Mu-
nich) and Austrian (Vienna) poisons centres between January 2002 and December 2013. The
data, entered by physicians, included age, sex, weight, ingested drug and dose, symptoms/
signs/laboratory values and causal relationship, severity of intoxication, decontamination mea-
sures, latency to decontamination, and therapeutic interventions.
Circumstances and symptoms of overdose
The circumstances of overdose were categorised as `suicidal`for cases of intentional overdose,
`domestic`for cases of accidental overdose in the home (primarily in children) and `iatrogen-
ic`for those due to a prescribing or administration error in hospital.
The severity of symptoms were graded in accordance with the Poisoning Severity Score
(PSS) as ‘minor’, for mild, transient and spontaneously resolving symptoms/signs; ‘moderate’,
if at least one pronounced or prolonged symptom/sign was recorded; ‘severe’, if at least one se-
vere or life-threatening symptom/sign was observed, or `fatal`, if the overdose was the recorded
cause of death [9].
Cases were assessed for association between symptoms or signs and the immunosuppressant
overdose by an expert panel including a senior clinical pharmacologist and a senior clinical toxi-
cologist, both with additional qualifications in general internal medicine, using the World Health
Organisation Uppsala Monitoring Centre (WHO-UMC) standardised case causality assessment
criteria originally developed for the assessment of adverse drug reactions [10]. Comorbidities,
co-ingestion of other medication (in patients with multiple drug overdose or taking other drugs
in the therapeutic dose range) and the magnitude of overdose were taken into consideration. As-
sociations were classified as `certain`, `likely`, `possible`and `unlikely`(Table A in S1 File).
Statistical analyses
Overdoses in mg/kg were compared with usual therapeutic doses by determining the multiple
of the subject`s usual therapeutic dose (dose received/usual dose) as performed in our previous
studies [11–13]. Sirolimus is not licensed for children under the age of 13 years, so no calcula-
tion of the extent of overdose could be made. Missing data regarding patient weight was com-
puted as detailed in Section A of the S1 File.
Pharmacokinetic calculations
Half-life, clearance/bioavailability and apparent volume of distribution were calculated accord-
ing to the standard pharmacokinetic equations given in Section A of the S1 File and PKSolver
for Microsoft Excel was used for graphic representation [14].
Results
There were a total of 367,445 reports to the Swiss Toxicological Information Centre of con-
firmed or suspected overdose with any substance by healthcare professionals during the study
Acute Sirolimus Overdose
PLOS ONE | DOI:10.1371/journal.pone.0128033 May 28, 2015 3 / 9
period. Of these, three were with sirolimus (Table 1 patients 1–3). Two cases were reported to
German poisons centres during the same time period (Table 1 patients 4 and 5). There were no
reports to the Austrian poisons centre.
Circumstance of overdose
Tables 1 and 2 show the subjects’ characteristics and the circumstances of overdose. Three of
the five cases (60%) involved accidental overdose in young children in the home-setting, one
case of overdose was with suicidal intent and one involved an iatrogenic administration error.
Magnitude of overdose
The magnitude of overdose above a patient`s usual maintenance dose or any dose above the
maximum licensed dose in treatment-naïve individuals is shown in Table 2. Drug
Table 1. Patient demographics, circumstances of overdose and overdose amount.
Patient Age
(years)
Sex Weight
(kg)
Underlying
condition
Circumstance
of overdose
Mono
Intoxication
Formulation Dose (mg) Dose
(mg/
kg)
Subject's
usual dose
(mg/d)
1 2.5 m 13 None Domestic Y tablets 3 0.23 0
2 3 f 15 None Domestic N tablets 2 0.13 0
3 18 f 55.8a Liver
transplantation
(Wilson`s disease)
Suicidal Y tablets 103 1.85 1.5
4 1.9 m 13 None Domestic Y tablets max. 7 max.
0.54
0
5 58 m 84 Renal
transplantation
Iatrogenic Y oral
suspension
1.1
(equivalent to
6.7 mg oralb)
0.08 uk
Abbreviations: f = female, i.v. = intravenous, m = male, max. = maximum, N = no, uk = unknown, Y = yes.
aweight not available so mean weight given (see Section A of the S1 File)
bassuming concomitant ciclosporin therapy).
doi:10.1371/journal.pone.0128033.t001
Table 2. Overdosage as amultiple of the patient’s usual dose (or factor abovemaximum licensed dose), decontamination measures and clinical
findings.
Patient Multiple of usual or maximum
licensed dose
Management Clinical ﬁndings (within number of days
after overdose)
Severity Relatedness to
overdose
1 n/a Single dose charcoal 1g/
kg
Increased alkaline phosphatase (<2-fold)
(2)
Mild Probable
Admission to hospital Fever (2) Mild Probable
Gastroenteritis (2) Moderate Probable
2 n/a uk Asymptomatic (within 1 h of overdose)
3 68.7 Transfer to psychiatry
service
Tiredness (1) Mild Possible
Elevated total cholesterol (4) Mild Probable
4 n/a Admission to hospital for
2 days
Asymptomatic (2)
5 1.1a No speciﬁc measures Asymptomatic (7 h after overdose)
h = hours, max. = maximum, n/a = not applicable, uk = unknown.
a maximum licensed dose in combination with cyclosporine used to determine degree of overdose as patient`s usual dose was not known.
doi:10.1371/journal.pone.0128033.t002
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concentration measurements were only available in two cases (patients 1 and 3). Patient 1
had a sirolimus blood concentration of 67.9 μg/L four hours after overdose. Patient 3 under-
went serial drug concentration monitoring in order to determine the time for recommencing
treatment with sirolimus. The maximum measured whole-blood sirolimus concentration was
127.6 μg/L 24 h after overdose. The concentration-time profile is shown in Fig 1. The patient
did not receive sirolimus again until at least 20 days after the overdose. As sirolimus has an
oral bioavailability of 15% (when co-administered with cyclosporine) [1], the intravenous ap-
plication of 1.1 mg in patient 5 was considered approximately equivalent to an oral dose of
6.7 mg (Table 1).
Signs and symptoms
Signs and symptoms associated with overdose were generally mild (Table 2). There were no
life-threatening events. Patient 3, who ingested the largest amount was closely followed but did
not show any changes in liver function tests or complete blood count.
Management
Three patients were hospitalised for at least 24 h. Care was transferred from acute medical to
psychiatric in-patient services in one case.
Activated charcoal was administered in patient 1 who presented to the emergency services
within four hours of overdose. Patient 3 presented 24 h after overdose, so activated charcoal
was not given. Follow-up blood counts and liver function tests were performed in three patients
(1, 3 and 4). Serum cholesterol and triglycerides were also measured in patient 3.
Fig 1. Semi-logarithmic plot of sirolimus concentration vs. time in a single case of overdose with 103
mg (Patient 3).Measurements commenced 24 hours after overdose.
doi:10.1371/journal.pone.0128033.g001
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Outcome of overdose
Two sirolimus overdoses were judged to have caused or contributed to symptoms or abnormal
clinical findings (Table 2). Patient 1 developed one minor and two moderate symptoms (in-
creased liver enzymes, fever and gastroenteritis) two days after the event. Patient 3 complained
of tiredness and showed a spontaneous decline in total cholesterol levels several days after over-
dose which implied that overdose was associated with an elevation in total cholesterol (Fig 2).
Triglyceride concentrations were not above the normal range and did not change significantly
from day 4 to day 67 post-overdose (data not shown).
Pharmacokinetic calculations
Visual inspection of the data presented in Fig 1 indicates at least a two-compartment system.
Due to the fact that the first whole blood sirolimus concentration measurement was made 24 h
after overdose, it is not possible to determine whether a two- or three-compartment model best
fits the data. Pharmacokinetic parameters were determined for the compartments according to
the methods given in Section A of the S1 File as shown in Table 3.
Discussion
In this observational case-series analysis of sirolimus overdoses reported to poisons centres
within Germany, Austria and Switzerland between 2002 and 2013, we found that acute over-
doses appear to be generally well tolerated, with no life-threatening events observed.
Fig 2. Total serum cholesterol concentration after overdose. The first measurement was taken four days after overdose.
doi:10.1371/journal.pone.0128033.g002
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Circumstances and magnitude of overdose
In this series, three of the five overdoses occurred accidentally in children at home and one iat-
rogenically in the hospital setting. The latter case involved a liquid formulation, which we have
observed to be associated with drug-errors involving other immunosuppressants [11]. There-
fore, 80% of the overdoses could have been prevented. Doctors who prescribe and pharmacists
who dispense sirolimus should therefore be extra vigilant when dealing with unusual formula-
tions and/or administration routes and patients who live with young children. Perhaps repeat-
ed instruction to keep medicines out of children’s`reach is required and not just when
sirolimus is dispensed for the first time. Due to the fact that absorption and metabolism of siro-
limus is so varied between patients, different patients require different doses to achieve the de-
sired therapeutic effect. An overdose was therefore considered to have taken place when this
dose was exceeded, and is the reason why we report the multiple of the subject`s usual thera-
peutic dose in the two patients who were being treated with sirolimus.
Management
On the basis of its chemical properties, a good adsorption of sirolimus onto activated charcoal
is to be expected. Sirolimus has a molecular weight of 914.17 Dalton, which means that it is ex-
pected to be readily adsorbed into the 10–1000 Å-sized charcoal pores of current activated
charcoal products [15]. Treatment with activated charcoal in cases presenting to health care
services within two hours of overdose therefore seems reasonable.
Signs and symptoms
In one case, elevated alkaline phosphatase, fever and gastroenteritis occurred two days after over-
dose, and in another total serum cholesterol levels reduced steadily after overdose, the latter im-
plying a concentration-dependent effect of sirolimus as found in other studies [3]. Dyslipidaemia
is a well-known dose-dependent adverse effect of mTOR inhibitors that is thought to occur
through down-regulation of low-density lipoprotein receptors and inhibition of lipoprotein li-
pase activity [16]. Elevated triglyceride concentrations are known to be more strongly dose-relat-
ed than cholesterol concentrations [3] and may have been present early after overdose in patient
3, however no measurements were performed during this time so it is not possible to comment.
It could be speculated that the high serum concentration and long half-life of sirolimus led
to significant immunosuppression in patient 1 (a young child) which increased his susceptibili-
ty to intercurrent infection.
Pharmacokinetic profile
Twenty-four hours after taking 103 mg of sirolimus, patient 3`s sirolimus blood concentration
was 127.6 μg/L. By way of comparison, 6 healthy, male, adult volunteers had a mean maximum
Table 3. Calculated pharmacokinetic parameters t1/2 = half-life, Vd/F = apparent volume of distribu-
tion, Cl/F = apparent clearance.
1st compartment* 2nd compartment
t1/2 (h) 51.7 190
Vd/F (L/kg) 0.9 -
Cl/F (L/h/kg) 0.139 -
* The term “compartment” refers to a volume of body ﬂuid into which a drug distributes. Examples of
compartments include blood plasma, interstitial ﬂuid and fat tissue.
doi:10.1371/journal.pone.0128033.t003
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sirolimus concentration (Cmax) of 47.6 μg/L after intake of a single 5 mg/m2 dose (approxi-
mately 9 mg for an average-sized man) [14].
Several pharmacokinetic studies of sirolimus have shown it to fit a two-compartment
model, as we also saw in patient 3 [17, 18]. A pharmacokinetic study of single-dose sirolimus
in 16 stable renal transplant recipients (receiving concomitant cyclosporine and prednisone)
found a range of half-lives from 39.3 to 86.5 h (compare 51.6 h in patient 3 in the present
study) and an 8-fold difference in apparent clearance (0.042 to 0.339 L/h/kg) [18]. The calculat-
ed apparent first compartment clearance found in patient 3 of 0.139 L/h/kg falls within this
range (Table 3). The apparent volume of distribution for the first (`central`) compartment (0.9
L/kg) is in keeping with sirolimus`protein binding and distribution in blood cells [1] and was
also in the range reported by Wu and colleagues in a population pharmacokinetics study (53.4
L) [19]. Although it is not possible to draw conclusions from a single case, the pharmacokinet-
ics of sirolimus in overdose appear to be similar to what is seen in the therapeutic dose range.
Limitations
Our study has a number of limitations, primarily related to the small sample size. Larger series
of sirolimus overdoses have, however, not been published. It is likely that our data did not cap-
ture all cases of overdose which occurred in the referral population. Our data are also incom-
plete, which is the nature of retrospective studies using poison centre data [20], and in one case
(patient 5), concomitant cyclosporine intake was assumed. A further limitation is the paucity
of data regarding whole blood concentration measurements.
Sirolimus overdose patterns, management and outcomes require further study and clinical
toxicologists, nephrologists and treating physicians should be encouraged to actively seek fol-
low-up data on the cases with which they are involved. Further preventive measures are re-
quired to reduce the frequency of iatrogenic errors involving liquid formulations and
accidental poisoning of children in the home.
Supporting Information
S1 File. Supporting information regarding materials and methods and pharmacokinetic
calculations (Section A) andWorld Health Organisation Uppsala Monitoring Centre
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